The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Mitochondrial fatty acid oxidation disorders: clinical presentation of long‐chain fatty acid oxidation defects before and after newborn screening
Abstract
The different long‐chain fatty acid oxidation defects present with similar heterogeneous clinical phenotypes of different severity. Organs mainly affected comprise the heart, liver, and skeletal muscles. All symptoms are reversible with sufficient energy supply. In some long‐chain fatty acid oxidation defects, disease‐specific symptoms occur. Only in disorders of the mitochondrial trifunctional protein (TFP) complex, including long‐chain 3‐hydroxyacyl‐coenzyme A (CoA) dehydrogenase (LCHAD) deficiency, neuropathy and retinopathy develop that are progressive and irreversible despite current treatment measures. In most long‐chain fatty acid oxidation defects, no clear genotype–phenotype correlation exists due to molecular heterogeneity. However, some isolated mutations have been identified to be associated with only mild phenotypes, e.g., the V243A mutation in very‐long‐chain acyl‐CoA dehydrogenase (VLCAD) deficiency. LCHAD deficiency is due to the prevalent homozygous 1528G>C mutation and presents with heterogeneous clinical phenotypes, suggesting the importance of other environmental and genetic factors. For some disorders, it was shown that residual enzyme activity measured in fibroblasts or lymphocytes correlated with severity of clinical phenotype. Implementation of newborn screening has significantly reduced morbidity and mortality of long‐chain fatty acid oxidation defects. However, the severest forms of TFP deficiency are still highly associated with neonatal death. Newborn screening also identifies a great number of mildly affected patients who may never develop clinical symptoms throughout life. However, later‐onset exercise‐induced myopathic symptoms remain characteristic clinical features of long‐chain fatty acid oxidation defects. Disease prevalence has increased with newborn screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects
BONNEFONT, J. (2004) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.06.004 · Cited by 637
Disorders of mitochondrial fatty acyl‐CoA β‐oxidation
Wanders, R. J. A., Vreken, P., den Boer, M. E. J., Wijburg, F. A., Van Gennip, A. H., & IJlst, L. (1999) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005504223140 · Cited by 257
Cited by
Acylcarnitines—old actors auditioning for new roles in metabolic physiology
McCoin, C. S., Knotts, T. A., & Adams, S. H. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.129 · Cited by 344
Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle
Knottnerus, S. J. G., Bleeker, J. C., Wüst, R. C. I., Ferdinandusse, S., IJlst, L., Wijburg, F. A., Wanders, R. J. A., Visser, G., & Houtkooper, R. H. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9448-1 · Cited by 331
ACG Clinical Guideline: Liver Disease and Pregnancy
Tran, T. T., Ahn, J., & Reau, N. S. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.430 · Cited by 304
Metadata
- Authors
- Spiekerkoetter, U.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2010-05-07
- Volume
- 33
- Issue
- 5
- Pages
- 527-532
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2073972671
- Cited by
- 170
- References
- 2
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mitochondrial fatty acid oxidation disorders: clinical presentation of long‐chain fatty acid oxidation defects before and after newborn screening. https://app.cochat.ai/papers/10.1007/s10545-010-9090-x
- The paper
- Spiekerkoetter, U. (2010). Mitochondrial fatty acid oxidation disorders: clinical presentation of long‐chain fatty acid oxidation defects before and after newborn screening. Journal of Inherited Metabolic Disease. https://doi.org/10.1007/s10545-010-9090-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.